| 4001 | PFDN5 levels | GCST90242340 | 0.36 |
| 4002 | Cholesteryl ester levels in very large VLDL | GCST90093018 | 0.36 |
| 4003 | BA-exvivo rh area BA4a | GCST90003225 | 0.36 |
| 4004 | CDKN1A/TMSB10 ratio | GCST90313978 | 0.36 |
| 4005 | IDP dMRI TBSS MD Posterior limb of internal capsule R | GCST90004045 | 0.36 |
| 4006 | GUCA2A levels | GCST90469418 | 0.36 |
| 4007 | Coxarthrosis [arthrosis of hip] | Arthrosis | UKBB00000154 | 0.36 |
| 4008 | LY75 levels | GCST90469822 | 0.36 |
| 4009 | Glucose levels (UKB data field 30740) | GCST90468071 | 0.36 |
| 4010 | IDP dMRI TBSS L2 Posterior corona radiata L | GCST90004150 | 0.36 |
| 4011 | CEP112 levels | GCST90468708 | 0.36 |
| 4012 | Free cholesterol to total lipids ratio in large LDL | GCST90092861 | 0.36 |
| 4013 | Phospholipids to total lipids in medium VLDL percentage (UKB data field 23594) | GCST90269691 | 0.36 |
| 4014 | FAM171B levels | GCST90469183 | 0.36 |
| 4015 | IDP dMRI ProbtrackX FA cst r | GCST90003934 | 0.36 |
| 4016 | CAG-776 sp000438195 abundance in stool | GCST90032296 | 0.36 |
| 4017 | Stearoylcarnitine (C18) levels | GCST90199743 | 0.36 |
| 4018 | Pain type(s) experienced in last month - Knee pain | Pain | UKBB00000629 | 0.36 |
| 4019 | Omega-6 fatty acid levels | GCST90502518 | 0.36 |
| 4020 | AXL/GAS6 ratio | GCST90313419 | 0.36 |
| 4021 | aparc-a2009s rh volume G-cingul-Post-ventral | GCST90003008 | 0.36 |
| 4022 | AGR2 levels | GCST90468253 | 0.36 |
| 4023 | Concentration of large LDL particles (UKB data field 23530) | GCST90269627 | 0.36 |
| 4024 | Arm fat-free mass (right) | Impedance measures | UKBB00000048 | 0.36 |
| 4025 | aparc-DKTatlas lh volume caudalanteriorcingulate | GCST90002863 | 0.35 |
| 4026 | Other neurological diseases | FING00001074 | 0.35 |
| 4027 | Reticulocyte percentage (UKB data field 30240) | GCST90468101 | 0.35 |
| 4028 | aparc-DKTatlas rh volume parahippocampal | GCST90002907 | 0.35 |
| 4029 | Volume of left cortico-amygdaloid transition area | GCST90474880 | 0.35 |
| 4030 | CPB1 levels | GCST90468839 | 0.35 |
| 4031 | Ectropion or entropion (PheCode 374.1) | GCST90475891 | 0.35 |
| 4032 | Triglycerides to total lipids ratio in very large HDL | GCST90093015 | 0.35 |
| 4033 | Hemoglobin A1c (HbA1c, maximum, inv-norm transformed) | GCST90475091 | 0.35 |
| 4034 | HDL cholesterol | Blood biochemistry | UKBB00000306 | 0.35 |
| 4035 | HippSubfield rh volume Whole-hippocampus | GCST90002711 | 0.35 |
| 4036 | IDP T1 FIRST brain stem+4th ventricle volume | GCST90002450 | 0.35 |
| 4037 | Urticaria | FING00001408 | 0.35 |
| 4038 | Free Cholesterol to Total Lipids in IDL percentage | GCST90497579 | 0.35 |
| 4039 | Fibrosis and cirrhosis of liver | FING00000543 | 0.35 |
| 4040 | IDP T1 FAST ROIs R caudate | GCST90002550 | 0.35 |
| 4041 | Left-hemisphere dorsal attention network to right-hemisphere somatomotor network white-matter structural connectivity | GCST90302695 | 0.35 |
| 4042 | CD27/CD79B ratio | GCST90313770 | 0.35 |
| 4043 | X-12100--hydroxytryptophan levels | GCST90243702 | 0.35 |
| 4044 | TPPP3 levels | GCST90470948 | 0.35 |
| 4045 | Treatment/medication code - perindopril | Medications | UKBB00000854 | 0.35 |
| 4046 | DTI autoptx MD atr l tract | GCST90385222 | 0.35 |
| 4047 | Triacylglycerol (52:4) [NL-16:0] levels | GCST90025170 | 0.35 |
| 4048 | ZNF830 levels | GCST90471102 | 0.35 |
| 4049 | Bioavailable testosterone levels | GCST90012104 | 0.35 |
| 4050 | Never eat wheat vs no wheat restrictions (UKB data field 6144) | GCST90132932 | 0.35 |
| 4051 | OSM/TGFA ratio | GCST90315590 | 0.35 |
| 4052 | Cholesterol levels in large VLDL | GCST90092868 | 0.35 |
| 4053 | Treatment speciality of consultant (recoded) - General surgery | Summary Administration | UKBB00000834 | 0.34 |
| 4054 | Reticulocyte count (UKB data field 30250) | GCST90468100 | 0.34 |
| 4055 | Concentration of very large VLDL particles | GCST90093023 | 0.34 |
| 4056 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T335 | ECGU000335 | 0.34 |
| 4057 | Disorders of iron metabolism (PheCode 275.1) | GCST90475743 | 0.34 |
| 4058 | Diacylglycerol_34:3_[M+H-H2O]1+ levels | GCST90060177 | 0.34 |
| 4059 | ICD10 N92: Excessive, frequent and irregular menstruation | GCST90454221 | 0.34 |
| 4060 | Phospholipids to Total Lipids in Medium LDL percentage | GCST90498847 | 0.34 |
| 4061 | FKBP4/FKBP5 ratio | GCST90314838 | 0.34 |
| 4062 | IDP dMRI ProbtrackX ISOVF slf l | GCST90004546 | 0.34 |
| 4063 | Crohns disease | GCST90468121 | 0.34 |
| 4064 | Free cholesterol levels in very large HDL | GCST90132680 | 0.34 |
| 4065 | KL levels | GCST90091246 | 0.34 |
| 4066 | Cholesterol to Total Lipids in Large LDL percentage | GCST90497938 | 0.34 |
| 4067 | Early onset COPD | FING00000485 | 0.34 |
| 4068 | Cholesteryl Esters in Medium VLDL | GCST90498928 | 0.34 |
| 4069 | ICAM1/SELE ratio | GCST90315116 | 0.34 |
| 4070 | IDP T1 FAST ROIs L precentral gyrus | GCST90002463 | 0.34 |
| 4071 | Cholesteryl ester_18:2_[M+NH4]1+ levels | GCST90060220 | 0.34 |
| 4072 | IDP dMRI ProbtrackX FA ptr l | GCST90003944 | 0.34 |
| 4073 | Diseases of hair and hair follicles (PheCode 704) | GCST90476209 | 0.34 |
| 4074 | VAT1 levels | GCST90471029 | 0.34 |
| 4075 | Myopia | FING00000853 | 0.34 |
| 4076 | HSBP1 levels | GCST90469481 | 0.34 |
| 4077 | Malignant neoplasm of bladder, excluding all cancers (controls excluding all cancers) | FING00000751 | 0.34 |
| 4078 | Arm predicted mass (left) | Impedance measures | UKBB00000049 | 0.33 |
| 4079 | Triglyceride to HDL cholesterol ratio | GCST90295953 | 0.33 |
| 4080 | Adenomyosis (Endometriosis of uterus) | FING00000042 | 0.33 |
| 4081 | IDP dMRI TBSS MO Posterior limb of internal capsule L | GCST90003971 | 0.33 |
| 4082 | SERPINA7 levels | GCST90470587 | 0.33 |
| 4083 | IFI30 levels | GCST90469509 | 0.33 |
| 4084 | aparc-a2009s lh volume G+S-subcentral | GCST90002928 | 0.33 |
| 4085 | DKK1 levels | GCST90012060 | 0.33 |
| 4086 | PRKAB1 levels | GCST90470324 | 0.33 |
| 4087 | Free cholesterol to total lipids ratio in medium VLDL | GCST90092921 | 0.33 |
| 4088 | IBD (strict) with PSC | FING00000657 | 0.33 |
| 4089 | Docosahexaenoic acid to total fatty acids percentage | GCST90501997 | 0.33 |
| 4090 | FAM177A1 levels | GCST90242458 | 0.33 |
| 4091 | Omega-3 fatty acids to total fatty acids percentage | GCST90502460 | 0.33 |
| 4092 | DTI autoptx FA slf r tract | GCST90385134 | 0.33 |
| 4093 | Atrial fibrillation and flutter | FING00000126 | 0.33 |
| 4094 | Smoking/smokers in household | Smoking | UKBB00000783 | 0.33 |
| 4095 | Nervonoylcarnitine (C24:1) levels | GCST90200143 | 0.33 |
| 4096 | Linoleic acid levels | GCST90092880 | 0.33 |
| 4097 | DTI autoptx L2 fmi tract | GCST90385177 | 0.33 |
| 4098 | Phosphatidylcholine-O_36:4_[M+H]1+/Phosphatidylcholine-P_36:3_[M+H]1+ levels | GCST90060318 | 0.33 |
| 4099 | GZMB/IL15 ratio | GCST90315015 | 0.33 |
| 4100 | DCTN6/TDRKH ratio | GCST90314436 | 0.33 |
| 4101 | Triacylglycerol (54:1) [NL-18:1] levels | GCST90024563 | 0.33 |
| 4102 | CD46 levels | GCST90468634 | 0.33 |
| 4103 | aparc-a2009s lh area Pole-temporal | GCST90003339 | 0.32 |
| 4104 | COPD-related respiratory insufficiency | FING00000352 | 0.32 |
| 4105 | Direct low density lipoprotein levels (UKB data field 30780) | GCST90468080 | 0.32 |
| 4106 | Heart failure | GCST90399712 | 0.32 |
| 4107 | CCL28/PDGFB ratio | GCST90313695 | 0.32 |
| 4108 | IDP dMRI ProbtrackX MD cst l | GCST90004227 | 0.32 |
| 4109 | Cholesteryl esters to total lipids ratio in large VLDL | GCST90092871 | 0.32 |
| 4110 | BGLAP levels | GCST90468440 | 0.32 |
| 4111 | Cholesteryl ester levels in large VLDL | GCST90092870 | 0.32 |
| 4112 | SULT1A1 levels | GCST90470781 | 0.32 |
| 4113 | AHSP levels | GCST90468264 | 0.32 |
| 4114 | EGF/GP6 ratio | GCST90314608 | 0.32 |
| 4115 | Type 2 diabetes | GCST90018706 | 0.32 |
| 4116 | 3-Hydroxybutyrate levels | GCST90092811 | 0.32 |
| 4117 | Papillary adenocarcinoma of thyroid gland, excluding all cancers (controls excluding all cancers) | FING00001143 | 0.32 |
| 4118 | FOXO3/SH2B3 ratio | GCST90314881 | 0.32 |
| 4119 | Left-hemisphere control network to right-hemisphere somatomotor network white-matter structural connectivity | GCST90302746 | 0.32 |
| 4120 | LDL direct, adjusted by medication | Lipid or lipoprotein measurement | UKBB00000388 | 0.32 |
| 4121 | IDP dMRI TBSS MD Sagittal stratum L | GCST90004058 | 0.32 |
| 4122 | NT5C1A levels | GCST90470090 | 0.32 |
| 4123 | Right-hemisphere control network to right-hemisphere control network white-matter structural connectivity | GCST90302834 | 0.32 |
| 4124 | Left-hemisphere somatomotor network to left-hemisphere salience/ventral attention network white-matter structural connectivity | GCST90302671 | 0.32 |
| 4125 | Medication use (diuretics) | GCST90018765 | 0.32 |
| 4126 | HS6ST1/MEGF9 ratio | GCST90315081 | 0.32 |
| 4127 | Anterior thigh muscle volume | GCST90267349 | 0.32 |
| 4128 | Hereditary hemolytic anemias (PheCode 282) | GCST90475779 | 0.31 |
| 4129 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T87 | ECGU000087 | 0.31 |
| 4130 | Histidine levels | GCST90243404 | 0.31 |
| 4131 | Peripheral enthesopathies and allied syndromes | musculoskeletal | UKBB00000640 | 0.31 |
| 4132 | Fasting glucose | GCST90002232 | 0.31 |
| 4133 | ANXA3/SERPINB1 ratio | GCST90313289 | 0.31 |
| 4134 | Prescriptions - angiotensin receptor blocker|anti-hypertensive|ARB | UKBB00000662 | 0.31 |
| 4135 | Myocardial fractal dimension (slice 2) | GCST90000288 | 0.31 |
| 4136 | Triglyceride levels in small VLDL | GCST90132667 | 0.31 |
| 4137 | Malignant neoplasm of breast, ER-positive, excluding all cancers (controls excluding all cancers) | FING00000754 | 0.31 |
| 4138 | Left ventricular stroke volume | GCST90268130 | 0.31 |
| 4139 | FADD/PTPN6 ratio | GCST90314775 | 0.31 |
| 4140 | Diastolic blood pressure (UKB data field 4079) | GCST90468163 | 0.31 |
| 4141 | Saturated fatty acids levels | GCST90499953 | 0.31 |
| 4142 | APOB levels | GCST90269536 | 0.31 |
| 4143 | COPD/asthma/ILD related infections | FING00000353 | 0.31 |
| 4144 | Total phospholipid levels in lipoprotein particles | GCST90092991 | 0.31 |
| 4145 | HDL cholesterol | GCST002223 | 0.31 |
| 4146 | LDL direct, adjusted by medication | Lipid or lipoprotein measurement | UKBB00000387 | 0.31 |
| 4147 | Triglycerides to total lipids in medium HDL percentage (UKB data field 23643) | GCST90269740 | 0.31 |
| 4148 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T260 | ECGA000260 | 0.31 |
| 4149 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T220 | ECGA000220 | 0.31 |
| 4150 | DTI TBSS MD Superior longitudinal fasciculus R | GCST90384612 | 0.31 |
| 4151 | CIAPIN1/SPARC ratio | GCST90314069 | 0.31 |
| 4152 | Mouth/teeth dental problems - None of the above | Mouth | UKBB00000489 | 0.31 |
| 4153 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T481 | ECGA000481 | 0.31 |
| 4154 | aseg rh volume Accumbens-area | GCST90002643 | 0.31 |
| 4155 | Cardiac conduction disorders (PheCode 426) | GCST90475952 | 0.31 |
| 4156 | Interpolated Year when operation took place | Operations | UKBB00000372 | 0.31 |
| 4157 | Total lipid levels in very large VLDL | GCST90093022 | 0.31 |
| 4158 | HS6ST2 levels | GCST90469480 | 0.31 |
| 4159 | DTI autoptx L3 str r tract | GCST90385217 | 0.31 |
| 4160 | Breast cancer | GCST90468117 | 0.31 |
| 4161 | KLK14 levels | GCST90469700 | 0.31 |
| 4162 | YAP1 levels | GCST90471086 | 0.30 |
| 4163 | Non-oily fish intake | Diet | UKBB00000525 | 0.30 |
| 4164 | Other alveolar and parietoalveolar pneumonopathy (PheCode 504) | GCST90476033 | 0.30 |
| 4165 | Cholesteryl Esters to Total Lipids in Medium VLDL percentage | GCST90498956 | 0.30 |
| 4166 | Operative procedures - Fibreoptic endoscopic snare resection of lesion of colon | Summary Operations | UKBB00000579 | 0.30 |
| 4167 | Hand grip strength (baseline) | GCST90565845 | 0.30 |
| 4168 | Left ventricular end diastole anterolateral wall thickness | GCST90278517 | 0.30 |
| 4169 | eGFR in diabetes mellitus (full adjustment) | GCST90624786 | 0.30 |
| 4170 | YTHDF3 levels | GCST90471091 | 0.30 |
| 4171 | ATOX1 levels | GCST90468385 | 0.30 |
| 4172 | aseg rh volume Hippocampus | GCST90002641 | 0.30 |
| 4173 | Histidine levels | GCST90092830 | 0.30 |
| 4174 | IDP dMRI ProbtrackX L2 cst r | GCST90004282 | 0.30 |
| 4175 | Chromatiales abundance in stool | GCST90032318 | 0.30 |
| 4176 | Hand grip strength right (UKB data field 47) | GCST90468169 | 0.30 |
| 4177 | rfMRI amplitudes (ICA100 node 44) | GCST90004632 | 0.30 |
| 4178 | aparc-Desikan rh volume lingual | GCST90002813 | 0.30 |
| 4179 | TIGIT levels | GCST90470865 | 0.30 |
| 4180 | Ceramide (d18:2/24:1) levels | GCST90024684 | 0.30 |
| 4181 | CXCL12/TIMP3 ratio | GCST90314338 | 0.30 |
| 4182 | ENDOU levels | GCST90469107 | 0.30 |
| 4183 | Macular pucker | FING00000745 | 0.30 |
| 4184 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T495 | ECGU000495 | 0.30 |
| 4185 | IFNGR1/IL10RB ratio | GCST90315127 | 0.30 |
| 4186 | ACTA2 levels | GCST90468208 | 0.30 |
| 4187 | DAG1 levels | GCST90468943 | 0.30 |
| 4188 | Presence of other functional implants | Persons with potential health hazards related to family and personal history and certain conditions influencing health status | UKBB00000709 | 0.29 |
| 4189 | Diacylglycerol (14:0_18:2) levels | GCST90024705 | 0.29 |
| 4190 | Cerebral aneurysm | GCST90018595 | 0.29 |
| 4191 | Diacylglycerol_33:1_[M+H-H2O]1+ levels | GCST90060173 | 0.29 |
| 4192 | CNTN3 levels | GCST90468805 | 0.29 |
| 4193 | F2R/SEMA4D ratio | GCST90314734 | 0.29 |
| 4194 | Cardiac pacemaker in situ (PheCode 426.91) | GCST90475960 | 0.29 |
| 4195 | Dermatitis | FING00000401 | 0.29 |
| 4196 | JPT2 levels | GCST90469663 | 0.29 |
| 4197 | Attention deficit hyperactivity disorder | GCST90568441 | 0.29 |
| 4198 | Cholesterol to total lipids in very small VLDL percentage (UKB data field 23605) | GCST90269702 | 0.29 |
| 4199 | Left-hemisphere control network to thalamus white-matter structural connectivity | GCST90302752 | 0.29 |
| 4200 | CD38 levels | GCST90468628 | 0.29 |
| 4201 | NELL1 levels | GCST90242481 | 0.29 |
| 4202 | Cholesterol to Total Lipids in Small VLDL percentage | GCST90499760 | 0.29 |
| 4203 | Cholesteryl Esters to Total Lipids in Small LDL percentage | GCST90499602 | 0.29 |
| 4204 | Polyglandular dysfunction | FING00001186 | 0.29 |
| 4205 | Colon polyps | GCST90475319 | 0.29 |
| 4206 | Total lipid levels in VLDL | GCST90092999 | 0.29 |
| 4207 | LAMP2 levels | GCST90469734 | 0.29 |
| 4208 | Omega-6 fatty acids to omega-3 fatty acids ratio | GCST90499194 | 0.29 |
| 4209 | Non-cancer illness code, self-reported - hypertension | Medical conditions | UKBB00000517 | 0.29 |
| 4210 | AmygNuclei lh volume Lateral-nucleus | GCST90002648 | 0.29 |
| 4211 | Acute upper respiratory infections | FING00000034 | 0.29 |
| 4212 | Other disorders of patella | FING00001032 | 0.28 |
| 4213 | NQO2 levels | GCST90242679 | 0.28 |
| 4214 | Familial combined hyperlipidemia defined by Mexico criteria | GCST90104007 | 0.28 |
| 4215 | Hypertrophy of breast | FING00000644 | 0.28 |
| 4216 | Concentration of small LDL particles | GCST90499669 | 0.28 |
| 4217 | Cholesteryl Esters to Total Lipids in Medium LDL percentage | GCST90498758 | 0.28 |
| 4218 | Phospholipids in small VLDL | GCST90499871 | 0.28 |
| 4219 | HS1BP3 levels | GCST90469477 | 0.28 |
| 4220 | Hypopotassemia (PheCode 276.14) | GCST90475755 | 0.28 |
| 4221 | Hair colour (natural, before greying): Red (UKB data field 1747_2) | GCST90041837 | 0.28 |
| 4222 | Linoleic acid to total fatty acids percentage | GCST90498328 | 0.28 |
| 4223 | Recent trouble relaxing | Anxiety | UKBB00000745 | 0.28 |
| 4224 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T96 | ECGA000096 | 0.28 |
| 4225 | CHGA levels | GCST90240699 | 0.28 |
| 4226 | PGF levels | GCST90011999 | 0.28 |
| 4227 | Biological Grandparent (maternal): Alzheimer's / Other Dementia | GCST90475484 | 0.28 |
| 4228 | METAP1D levels | GCST90469892 | 0.28 |
| 4229 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T126 | ECGU000126 | 0.28 |
| 4230 | Linoleic acid to total fatty acids percentage | GCST90502336 | 0.28 |
| 4231 | Sodium (mean, inv-norm transformed) | GCST90476395 | 0.28 |
| 4232 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T445 | ECGU000445 | 0.28 |
| 4233 | Myo-inositol levels | GCST90243527 | 0.28 |
| 4234 | HippSubfield rh volume CA4-body | GCST90002705 | 0.28 |
| 4235 | Treatment or medication use - ezetimibe (UKB data field 20003_1141192736) | GCST90042541 | 0.28 |
| 4236 | IDP dMRI TBSS L1 Posterior limb of internal capsule R | GCST90004093 | 0.28 |
| 4237 | BOLA2 or BOLA2B levels | GCST90468460 | 0.28 |
| 4238 | Osteoarthrosis | musculoskeletal | UKBB00000596 | 0.28 |
| 4239 | Gamma glutamyltransferase | Blood biochemistry | UKBB00000275 | 0.28 |
| 4240 | Glycated haemoglobin HbA1c levels (UKB data field 30750) | GCST90468072 | 0.28 |
| 4241 | aparc-DKTatlas rh volume lingual | GCST90002904 | 0.28 |
| 4242 | SCLY/SORD ratio | GCST90315816 | 0.28 |
| 4243 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T464 | ECGU000464 | 0.28 |
| 4244 | Average diameter for HDL particles | GCST90497454 | 0.28 |
| 4245 | Illnesses of mother - Diabetes | Family history | UKBB00000347 | 0.28 |
| 4246 | Multi-trait sum score | GCST90270119 | 0.28 |
| 4247 | Cellulitis and abscess of leg, except foot (PheCode 681.5) | GCST90476166 | 0.28 |
| 4248 | Myocardial infarction (PheCode 411.2) | GCST90043954 | 0.28 |
| 4249 | Free cholesterol levels in VLDL | GCST90092998 | 0.28 |
| 4250 | Non-cancer illness code, self-reported - type 2 diabetes | Medical conditions | UKBB00000522 | 0.28 |
| 4251 | CPB1/KIRREL2 ratio | GCST90314210 | 0.28 |
| 4252 | PDGFA/SPARC ratio | GCST90315620 | 0.27 |
| 4253 | Hyphaema and other vascular disorders of iris and ciliary body | FING00000647 | 0.27 |
| 4254 | SH2B3/SUGT1 ratio | GCST90315840 | 0.27 |
| 4255 | Concentration of LDL particles | GCST90092887 | 0.27 |
| 4256 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T127 | ECGU000127 | 0.27 |
| 4257 | Polyunsaturated fatty acids to total fatty acids percentage | GCST90499299 | 0.27 |
| 4258 | aseg rh volume Lateral-Ventricle | GCST90002633 | 0.27 |
| 4259 | Benign neoplasm: Rectum | FING00000196 | 0.27 |
| 4260 | Mean volume of bilateral amygdala | GCST90474997 | 0.27 |
| 4261 | Liver enzyme levels (gamma-glutamyl transferase) | GCST90013407 | 0.27 |
| 4262 | Hernia of abdominal wall, postoperative | FING00000618 | 0.27 |
| 4263 | Nonspecific chest pain | circulatory system | UKBB00000527 | 0.27 |
| 4264 | CLEC1B/PPP1R2 ratio | GCST90314101 | 0.27 |
| 4265 | Concentration of LDL particles (UKB data field 23429) | GCST90269526 | 0.27 |
| 4266 | Glycated hemoglobin levels | GCST90002244 | 0.27 |
| 4267 | TIMP3/ZBTB16 ratio | GCST90315921 | 0.27 |
| 4268 | Umbilical hernia | digestive | UKBB00000880 | 0.27 |
| 4269 | DTI TBSS L3 Superior longitudinal fasciculus R | GCST90384564 | 0.27 |
| 4270 | Vascular/heart problems diagnosed by doctor - High blood pressure | Medical conditions | UKBB00000898 | 0.27 |
| 4271 | Prescriptions - calcium channel blocker|dihydropyridine|anti-hypertensive | UKBB00000673 | 0.27 |
| 4272 | Diastolic blood pressure, combined automated + manual reading | Cardiovascular measurement | UKBB00000177 | 0.27 |
| 4273 | Triglycerides in small VLDL | GCST90499915 | 0.27 |
| 4274 | Cholesterol in Large HDL | GCST90497709 | 0.27 |
| 4275 | CLEC1B/DAB2 ratio | GCST90314086 | 0.27 |
| 4276 | TSPAN1 levels | GCST90470978 | 0.27 |
| 4277 | VLDL cholesterol levels | GCST90092996 | 0.27 |
| 4278 | Sleep apnea (MTAG) (adjusted for BMI) | GCST90267364 | 0.27 |
| 4279 | STC1 levels | GCST90470761 | 0.27 |
| 4280 | ITGA6 levels | GCST90469636 | 0.27 |
| 4281 | Cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) with severe ocular complications | GCST90093113 | 0.27 |
| 4282 | Linoleoyl-arachidonoyl-glycerol (18:2/20:4) [1] levels | GCST90200103 | 0.27 |
| 4283 | Right-hemisphere salience/ventral attention network to pallidum white-matter structural connectivity | GCST90302820 | 0.27 |
| 4284 | Asthma mixed form (mode) (more control exclusions) | FING00000116 | 0.27 |
| 4285 | IDP dMRI ProbtrackX L2 cgc l | GCST90004277 | 0.27 |
| 4286 | Free cholesterol to total lipids ratio in small VLDL | GCST90092973 | 0.27 |
| 4287 | Free cholesterol levels in medium VLDL | GCST90092920 | 0.27 |
| 4288 | AMBP/EFEMP1 ratio | GCST90313253 | 0.27 |
| 4289 | CEP43/MPHOSPH8 ratio | GCST90314019 | 0.27 |
| 4290 | NPTX2 levels | GCST90470079 | 0.27 |
| 4291 | CALCOCO1/CASP8 ratio | GCST90313597 | 0.26 |
| 4292 | PCSK9 levels | GCST90470177 | 0.26 |
| 4293 | Diastolic blood pressure, combined automated + manual reading | Cardiovascular measurement | UKBB00000176 | 0.26 |
| 4294 | KLK8 levels | GCST90422316 | 0.26 |
| 4295 | Takes medication for coronary artery/ coronary heart disease? | GCST90475199 | 0.26 |
| 4296 | Omega-3 fatty acid levels | GCST90502441 | 0.26 |
| 4297 | RBM17 levels | GCST90470434 | 0.26 |
| 4298 | Total cholesterol levels | GCST90018754 | 0.26 |
| 4299 | aparc-a2009s rh area G-cingul-Post-ventral | GCST90003380 | 0.26 |
| 4300 | wg lh intensity-contrast precuneus | GCST90003816 | 0.26 |
| 4301 | Prescriptions - alpha1-antagonist|alpha blocker | UKBB00000659 | 0.26 |
| 4302 | CD84/SORT1 ratio | GCST90313918 | 0.26 |
| 4303 | Frontotemporal dementia | FING00000560 | 0.26 |
| 4304 | IDP dMRI ProbtrackX L2 ilf r | GCST90004288 | 0.26 |
| 4305 | HMBS/PSMG3 ratio | GCST90315064 | 0.26 |
| 4306 | Acetoacetate levels (UKB data field 23476) | GCST90269573 | 0.26 |
| 4307 | Foveal thickness | GCST90624113 | 0.26 |
| 4308 | Random glucose levels | GCST90271557 | 0.26 |
| 4309 | EDAR levels | GCST90469068 | 0.26 |
| 4310 | Free cholesterol to total lipids in very small VLDL percentage (UKB data field 23607) | GCST90269704 | 0.26 |
| 4311 | PLA2G15/PRCP ratio | GCST90315661 | 0.26 |
| 4312 | Omega-3 fatty acids to total fatty acids percentage | GCST90499163 | 0.26 |
| 4313 | Concentration of small LDL particles | GCST90092963 | 0.26 |
| 4314 | IDP dMRI TBSS ISOVF Anterior corona radiata L | GCST90004500 | 0.26 |
| 4315 | GGT5 levels | GCST90469337 | 0.26 |
| 4316 | DTI TBSS L3 Splenium of corpus callosum | GCST90384528 | 0.26 |
| 4317 | Cholesterol to total lipids in chylomicrons and extremely large VLDL percentage (UKB data field 23580) | GCST90269677 | 0.26 |
| 4318 | Left-hemisphere default mode network to right-hemisphere salience/ventral attention network white-matter structural connectivity | GCST90302763 | 0.26 |
| 4319 | DNM1 levels | GCST90469021 | 0.26 |
| 4320 | Omega-3 fatty acids to total fatty acids percentage | GCST90502450 | 0.26 |
| 4321 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T497 | ECGU000497 | 0.25 |
| 4322 | Qualifications - CSEs or equivalent | Education | UKBB00000728 | 0.25 |
| 4323 | Cholesteryl ester levels in VLDL | GCST90092997 | 0.25 |
| 4324 | Gamma glutamyltransferase levels (UKB data field 30730) | GCST90468070 | 0.25 |
| 4325 | Cholesteryl ester levels in LDL | GCST90092884 | 0.25 |
| 4326 | CKAP4/LTBR ratio | GCST90314074 | 0.25 |
| 4327 | Systolic blood pressure | GCST90301696 | 0.25 |
| 4328 | SORT1/VSIR ratio | GCST90315870 | 0.25 |
| 4329 | CHMP6 levels | GCST90468747 | 0.25 |
| 4330 | Free Cholesterol to Total Lipids in Medium VLDL percentage | GCST90498976 | 0.25 |
| 4331 | Total Lipids in Medium LDL | GCST90498800 | 0.25 |
| 4332 | Familial combined hyperlipidemia defined by Dutch criteria | GCST90104005 | 0.25 |
| 4333 | Volume of right lateral nucleus | GCST90475034 | 0.25 |
| 4334 | Cholesterol to total lipids in medium HDL percentage (UKB data field 23640) | GCST90269737 | 0.25 |
| 4335 | Free cholesterol to total lipids ratio in medium LDL | GCST90092909 | 0.25 |
| 4336 | Uterine fibroids | GCST90461958 | 0.25 |
| 4337 | Attention deficit hyperactivity disorder (adjusted for age, sex) | GCST90275147 | 0.25 |
| 4338 | Glucose (fasting status unknown, mean, inv-norm transformed) | GCST90475332 | 0.25 |
| 4339 | DTI TBSS MD Cingulum cingulate gyrus L | GCST90384607 | 0.25 |
| 4340 | Cholesteryl ester levels in small VLDL | GCST90092970 | 0.25 |
| 4341 | TCN2 levels | GCST90470820 | 0.25 |
| 4342 | Other forms of systemic lupus erythematosus | FING00001051 | 0.25 |
| 4343 | Cholesterol levels in small VLDL | GCST90092968 | 0.25 |
| 4344 | Snoring | Sleep | UKBB00000784 | 0.25 |
| 4345 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T132 | ECGU000132 | 0.25 |
| 4346 | Thyrotoxicosis with or without goiter (PheCode 242) | GCST90475643 | 0.25 |
| 4347 | RUVBL1 levels | GCST90470509 | 0.25 |
| 4348 | Fracture of lower leg, including ankle | FING00000555 | 0.25 |
| 4349 | Phospholipid levels in very large HDL | GCST90132642 | 0.25 |
| 4350 | Estradiol levels | GCST90020091 | 0.25 |
| 4351 | Nephritis and nephropathy in diseases classified elsewhere (PheCode 580.31) | GCST90476116 | 0.25 |
| 4352 | ATP5IF1/HSPA1A ratio | GCST90313388 | 0.24 |
| 4353 | CD48/CRTAM ratio | GCST90313839 | 0.24 |
| 4354 | Benign neoplasm: Sigmoid colon | FING00000203 | 0.24 |
| 4355 | aseg global volume VentricleChoroid | GCST90002598 | 0.24 |
| 4356 | Degree of unsaturation | GCST90502734 | 0.24 |
| 4357 | CPM/PCSK9 ratio | GCST90314216 | 0.24 |
| 4358 | Cancer code, self-reported: breast cancer (UKB data field 20001_1002) | GCST90041886 | 0.24 |
| 4359 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T217 | ECGA000217 | 0.24 |
| 4360 | Total bile acid levels in pregnancy | GCST90454198 | 0.24 |
| 4361 | Total lipid levels in medium HDL | GCST90092898 | 0.24 |
| 4362 | Phospholipid levels in medium VLDL | GCST90092924 | 0.24 |
| 4363 | Intraocular pressure | GCST004074 | 0.24 |
| 4364 | Free cholesterol in medium LDL (UKB data field 23542) | GCST90269639 | 0.24 |
| 4365 | EBAG9/FKBP5 ratio | GCST90314564 | 0.24 |
| 4366 | DKK1/IPCEF1 ratio | GCST90314471 | 0.24 |
| 4367 | Cholesteryl Esters in Large HDL | GCST90497751 | 0.24 |
| 4368 | Urinary albumin excretion | GCST006586 | 0.24 |
| 4369 | DTI TBSS L1 Anterior corona radiata R | GCST90384450 | 0.24 |
| 4370 | CD300LG/CD93 ratio | GCST90313800 | 0.24 |
| 4371 | Takes medication for heart attack? | GCST90475212 | 0.24 |
| 4372 | Diacylglycerol_36:2_[M+H-H2O]1+ levels | GCST90060191 | 0.24 |
| 4373 | AKT2 levels | GCST90468277 | 0.24 |
| 4374 | aseg lh intensity Putamen | GCST90003770 | 0.24 |
| 4375 | High cholesterol | GCST90475205 | 0.24 |
| 4376 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T75 | ECGU000075 | 0.24 |
| 4377 | CRADD/STAMBP ratio | GCST90314244 | 0.24 |
| 4378 | PDGFB/ST6GAL1 ratio | GCST90315630 | 0.24 |
| 4379 | Familial combined hyperlipidemia defined by Consensus criteria | GCST90104006 | 0.24 |
| 4380 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T3 | ECGA000003 | 0.24 |
| 4381 | DTI TBSS L3 Superior longitudinal fasciculus L | GCST90384565 | 0.24 |
| 4382 | Concentration of medium VLDL particles | GCST90092923 | 0.24 |
| 4383 | Cholesteryl esters in very large HDL (UKB data field 23555) | GCST90269652 | 0.24 |
| 4384 | DTI TBSS MD Genu of corpus callosum | GCST90384574 | 0.24 |
| 4385 | Left-hemisphere limbic network to right-hemisphere limbic network white-matter structural connectivity | GCST90302733 | 0.24 |
| 4386 | IDP dMRI ProbtrackX L3 ilf r | GCST90004315 | 0.24 |
| 4387 | Total lipid levels in lipoprotein particles | GCST90500086 | 0.24 |
| 4388 | EBAG9/TBCB ratio | GCST90314567 | 0.24 |
| 4389 | DUSP29 levels | GCST90469052 | 0.24 |
| 4390 | OXCT1 levels | GCST90470138 | 0.24 |
| 4391 | aparc-Desikan lh volume parstriangularis | GCST90002787 | 0.24 |
| 4392 | CRELD2/HYOU1 ratio | GCST90314255 | 0.24 |
| 4393 | Free Cholesterol to Total Lipids in Large HDL percentage | GCST90497793 | 0.24 |
| 4394 | APOB/APOA1 ratio | GCST90092810 | 0.24 |
| 4395 | Osteoarthrosis, localized, primary (PheCode 740.11) | GCST90476255 | 0.24 |
| 4396 | IDP dMRI ProbtrackX L1 str r | GCST90004270 | 0.24 |
| 4397 | CIAPIN1/VEGFC ratio | GCST90314071 | 0.24 |
| 4398 | Triglycerides to total lipids ratio in very small VLDL | GCST90093039 | 0.24 |
| 4399 | USP8/WASF1 ratio | GCST90315944 | 0.23 |
| 4400 | Cholesteryl ester_16:0_[M+NH4]1+ levels | GCST90060211 | 0.23 |
| 4401 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T219 | ECGU000219 | 0.23 |
| 4402 | Brugada syndrome | GCST90295916 | 0.23 |
| 4403 | Cholesteryl esters to total lipids in very small VLDL percentage (UKB data field 23606) | GCST90269703 | 0.23 |
| 4404 | AmygNuclei rh volume Cortical-nucleus | GCST90002664 | 0.23 |
| 4405 | Polyunsaturated fatty acid levels | GCST90502133 | 0.23 |
| 4406 | ITM2A levels | GCST90469653 | 0.23 |
| 4407 | Collagenous colitis | GCST90204145 | 0.23 |
| 4408 | DTI TBSS MO Medial lemniscus L | GCST90384629 | 0.23 |
| 4409 | Triglycerides in very large VLDL | GCST90500680 | 0.23 |
| 4410 | IDP dMRI TBSS L2 Posterior thalamic radiation L | GCST90004152 | 0.23 |
| 4411 | Radiculopathy | FING00001238 | 0.23 |
| 4412 | HEXIM1/NT5C3A ratio | GCST90315048 | 0.23 |
| 4413 | THY1/TNFRSF21 ratio | GCST90315919 | 0.23 |
| 4414 | ALDH1A1/CA2 ratio | GCST90313243 | 0.23 |
| 4415 | PEPD levels | GCST90470209 | 0.23 |
| 4416 | Medication use (HMG CoA reductase inhibitors) | GCST90018769 | 0.23 |
| 4417 | wg lh intensity-contrast medialorbitofrontal | GCST90003805 | 0.23 |
| 4418 | HSPA1A levels | GCST90469487 | 0.23 |
| 4419 | Sjögren's syndrome | GCST90018700 | 0.23 |
| 4420 | Treatment speciality of consultant (recoded) - Ophthalmology | Summary Administration | UKBB00000835 | 0.23 |
| 4421 | Urine N-acetylglutamate levels in chronic kidney disease | GCST90265569 | 0.23 |
| 4422 | Redundant prepuce, phimosis and paraphimosis | FING00001246 | 0.23 |
| 4423 | IDP dMRI ProbtrackX L2 atr r | GCST90004276 | 0.23 |
| 4424 | FKBP1B/PRDX5 ratio | GCST90314833 | 0.23 |
| 4425 | ICD10 O13: Gestational hypertension | GCST90454232 | 0.23 |
| 4426 | ADH1B levels | GCST90468243 | 0.23 |
| 4427 | Glaucoma (primary open-angle) | GCST90399725 | 0.23 |
| 4428 | CD244/CRTAM ratio | GCST90313763 | 0.23 |
| 4429 | Autorefraction - 6mm asymmetry index (right) | Eyesight | UKBB00000074 | 0.23 |
| 4430 | DTI autoptx MD ptr l tract | GCST90385239 | 0.23 |
| 4431 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T464 | ECGA000464 | 0.23 |
| 4432 | Phospholipid levels in VLDL | GCST90093001 | 0.23 |
| 4433 | Antihypertensive medication - note that there are other indications | FING00000097 | 0.23 |
| 4434 | IDP dMRI TBSS MO Medial lemniscus L | GCST90003961 | 0.23 |
| 4435 | IDP dMRI ProbtrackX ISOVF ilf r | GCST90004540 | 0.23 |
| 4436 | BA-exvivo rh volume BA4a | GCST90002853 | 0.23 |
| 4437 | ANXA3/BID ratio | GCST90313279 | 0.23 |
| 4438 | Obstructive chronic bronchitis (PheCode 496.21) | GCST90476030 | 0.23 |
| 4439 | Congestive heart failure (CHF) NOS (PheCode 428.1) | GCST90475982 | 0.22 |
| 4440 | X-24328 levels | GCST90200624 | 0.22 |
| 4441 | VSIR levels | GCST90471053 | 0.22 |
| 4442 | 3,5-dichloro-2,6-dihydroxybenzoic acid levels | GCST90200252 | 0.22 |
| 4443 | total cholesterol (mean, inv-norm transformed) | GCST90476424 | 0.22 |
| 4444 | BSG/LAMP3 ratio | GCST90313533 | 0.22 |
| 4445 | RNASE1 levels | GCST90470476 | 0.22 |
| 4446 | Hyperlipidemia (PheCode 272.1) | GCST90475718 | 0.22 |
| 4447 | CEP43/WASF1 ratio | GCST90314023 | 0.22 |
| 4448 | TSPAN8 levels | GCST90470980 | 0.22 |
| 4449 | Mean arterial pressure, manual reading | Cardiovascular measurement | UKBB00000442 | 0.22 |
| 4450 | F2R/SERPINE1 ratio | GCST90314735 | 0.22 |
| 4451 | IDP dMRI TBSS L1 Retrolenticular part of internal capsule R | GCST90004095 | 0.22 |
| 4452 | ROBO2 levels | GCST90470490 | 0.22 |
| 4453 | Coronary artery / coronary heart disease (including heart attack, angina) | GCST90475198 | 0.22 |
| 4454 | BID levels | GCST90468444 | 0.22 |
| 4455 | Reticulocyte count | GCST004622 | 0.22 |
| 4456 | aparc-a2009s rh volume S-central | GCST90003043 | 0.22 |
| 4457 | Triglycerides to total lipids in large HDL percentage (UKB data field 23638) | GCST90269735 | 0.22 |
| 4458 | ThalamNuclei rh volume VLp | GCST90002755 | 0.22 |
| 4459 | wg rh intensity-contrast precuneus | GCST90003851 | 0.22 |
| 4460 | Blood cell traits latent factor 1 (white cell) | GCST90559243 | 0.22 |
| 4461 | MUC16 levels | GCST90469964 | 0.22 |
| 4462 | IDP dMRI TBSS MD Posterior corona radiata L | GCST90004054 | 0.22 |
| 4463 | Cholesteryl Esters to Total Lipids in Small VLDL percentage | GCST90499804 | 0.22 |
| 4464 | Clinical LDL cholesterol levels | GCST90497219 | 0.22 |
| 4465 | Cholesteryl esters to total lipids ratio in very large HDL | GCST90093007 | 0.22 |
| 4466 | CXCL11/ITGB1BP2 ratio | GCST90314335 | 0.22 |
| 4467 | Omega-3 fatty acid levels | GCST90502056 | 0.22 |
| 4468 | HippSubfield lh volume molecular-layer-HP-head | GCST90002677 | 0.22 |
| 4469 | CEACAM8 levels | GCST90468698 | 0.22 |
| 4470 | DTI autoptx L1 ilf r tract | GCST90385154 | 0.22 |
| 4471 | Barrett's esophagus | GCST003738 | 0.22 |
| 4472 | COX5B/GFER ratio | GCST90314200 | 0.22 |
| 4473 | Free cholesterol to total lipids in small VLDL percentage (UKB data field 23602) | GCST90269699 | 0.22 |
| 4474 | Chronic heart failure | GCST90018586 | 0.22 |
| 4475 | CRADD/FKBP4 ratio | GCST90314238 | 0.22 |
| 4476 | Campesterol levels | GCST90199725 | 0.22 |
| 4477 | Urinary albumin-to-creatinine ratio | GCST009640 | 0.22 |
| 4478 | EREG/ITGB1BP2 ratio | GCST90314703 | 0.21 |
| 4479 | Plasma methylsuccinoylcarnitine levels in chronic kidney disease | GCST90265508 | 0.21 |
| 4480 | Phospholipids in LDL (UKB data field 23413) | GCST90269510 | 0.21 |
| 4481 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T133 | ECGU000133 | 0.21 |
| 4482 | KLK11 levels | GCST90012012 | 0.21 |
| 4483 | TFF2 levels | GCST90470836 | 0.21 |
| 4484 | CRADD/SIRT2 ratio | GCST90314243 | 0.21 |
| 4485 | Cholesteryl Esters in Large LDL | GCST90497949 | 0.21 |
| 4486 | Umbilical hernia | Hernia | UKBB00000881 | 0.21 |
| 4487 | CDKN1A/ENO2 ratio | GCST90313969 | 0.21 |
| 4488 | Sphingomyelins levels | GCST90499983 | 0.21 |
| 4489 | GHRL levels | GCST90469341 | 0.21 |
| 4490 | Plasma X-26054 levels in chronic kidney disease | GCST90266858 | 0.21 |
| 4491 | Pulse pressure | GCST90301703 | 0.21 |
| 4492 | T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 2) | GCST90320565 | 0.21 |
| 4493 | Fracture of femur | FING00000552 | 0.21 |
| 4494 | APOB/APOA1 ratio | GCST90497158 | 0.21 |
| 4495 | KLB levels | GCST90469693 | 0.21 |
| 4496 | Lysoalkylphosphatidylcholine (O-24:0) levels | GCST90025436 | 0.21 |
| 4497 | Scar conditions and fibrosis of skin (PheCode 701.2) | GCST90476198 | 0.21 |
| 4498 | Pre-eclampsia | FING00001200 | 0.21 |
| 4499 | Total cholines levels | GCST90497185 | 0.21 |
| 4500 | FABP1 levels | GCST90469173 | 0.21 |
| 4501 | Triglycerides to phosphoglycerides ratio (UKB data field 23435) | GCST90269532 | 0.21 |
| 4502 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T455 | ECGU000455 | 0.21 |
| 4503 | 1,2-dipalmitoyl-GPC (16:0/16:0) metabolite level | GCST90615438 | 0.21 |
| 4504 | Free cholesterol levels in small VLDL | GCST90092972 | 0.21 |
| 4505 | DTI autoptx MD slf l tract | GCST90385241 | 0.20 |
| 4506 | CCL26 levels | GCST90468578 | 0.20 |
| 4507 | Cholesterol to total lipids in small LDL percentage (UKB data field 23625) | GCST90269722 | 0.20 |
| 4508 | Right ventricular end diastolic volume | GCST90268116 | 0.20 |
| 4509 | GRSF1 levels | GCST90469407 | 0.20 |
| 4510 | Body fat percentage (adjusted for testosterone and SHBG) x sex interaction | GCST90432181 | 0.20 |
| 4511 | Triglycerides to total lipids ratio in medium VLDL | GCST90092927 | 0.20 |
| 4512 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T61 | ECGA000061 | 0.20 |
| 4513 | Hypertensive Heart Disease | FING00000639 | 0.20 |
| 4514 | Proline levels | GCST90243457 | 0.20 |
| 4515 | PLXNA4/SUSD1 ratio | GCST90315689 | 0.20 |
| 4516 | HGFAC levels | GCST90469448 | 0.20 |
| 4517 | EDAR/SERPINB1 ratio | GCST90314586 | 0.20 |
| 4518 | N-acetylglycine levels | GCST90243561 | 0.20 |
| 4519 | PPL levels | GCST90470294 | 0.20 |
| 4520 | APP/NID2 ratio | GCST90313327 | 0.20 |
| 4521 | High light scatter reticulocyte count | Blood count | UKBB00000326 | 0.20 |
| 4522 | Excessive hairiness | GCST006095 | 0.20 |
| 4523 | Glycosyl-N-behenoyl-sphingadienine (d18:2/22:0) levels | GCST90200105 | 0.20 |
| 4524 | Autorefraction - 3mm strong meridian (left) | Eyesight | UKBB00000065 | 0.20 |
| 4525 | Palmar fascial fibromatosis [Dupuytren] | FING00001141 | 0.20 |
| 4526 | IDP dMRI TBSS ISOVF Sagittal stratum L | GCST90004508 | 0.20 |
| 4527 | Abdominal hernia | digestive | UKBB00000002 | 0.20 |
| 4528 | Multiple myeloma or monoclonal gammopathy of undetermined significance | GCST90624746 | 0.20 |
| 4529 | Impedance of arm (right) | Impedance measures | UKBB00000357 | 0.20 |
| 4530 | Omega-6 fatty acids to omega-3 fatty acids ratio | GCST90499199 | 0.20 |
| 4531 | Cholesteryl esters in HDL (UKB data field 23418) | GCST90269515 | 0.20 |
| 4532 | SNAP29/TJAP1 ratio | GCST90315861 | 0.20 |
| 4533 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T453 | ECGU000453 | 0.20 |
| 4534 | PLAT levels | GCST90470250 | 0.20 |
| 4535 | OPLAH levels | GCST90470127 | 0.20 |
| 4536 | Diastolic blood pressure, automated reading | Blood pressure | UKBB00000173 | 0.20 |
| 4537 | T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 95) | GCST90320658 | 0.20 |
| 4538 | Free cholesterol in small VLDL (UKB data field 23514) | GCST90269611 | 0.20 |
| 4539 | LZTFL1 levels | GCST90469834 | 0.20 |
| 4540 | Cholesterol to Total Lipids in Large HDL percentage | GCST90497730 | 0.20 |
| 4541 | Cholesteryl Esters in Small LDL | GCST90499586 | 0.20 |
| 4542 | SNX9 levels | GCST90470703 | 0.20 |
| 4543 | Omega-6 fatty acid levels | GCST90502100 | 0.19 |
| 4544 | CD99L2 levels | GCST90468657 | 0.19 |
| 4545 | PHYKPL levels | GCST90470228 | 0.19 |
| 4546 | Blood glucose levels | GCST90025986 | 0.19 |
| 4547 | Left-hemisphere visual network to right-hemisphere limbic network white-matter structural connectivity | GCST90302659 | 0.19 |
| 4548 | Cholesterol to total lipids ratio in medium VLDL | GCST90092917 | 0.19 |
| 4549 | Hemoglobin A1c levels | GCST90278632 | 0.19 |
| 4550 | CD40/TIMP3 ratio | GCST90313829 | 0.19 |
| 4551 | 1-palmitoyl-2-linoleoyl-GPC (16:0/18:2) metabolite level | GCST90616405 | 0.19 |
| 4552 | Diabetes / Sugar | GCST90475265 | 0.19 |
| 4553 | Nontoxic multinodular goitre | FING00000888 | 0.19 |
| 4554 | Type 2 diabetes | GCST010118 | 0.19 |
| 4555 | Right bundle branch block (PheCode 426.31) | GCST90475957 | 0.19 |
| 4556 | PRSS2 levels | GCST90470343 | 0.19 |
| 4557 | Free cholesterol to total lipids ratio in small LDL | GCST90092961 | 0.19 |
| 4558 | ATXN10 levels | GCST90468401 | 0.19 |
| 4559 | Diseases of arteries, arterioles and capillaries (FINNGEN) | FING00000423 | 0.19 |
| 4560 | All dysplastic lesions of the cervix uteri | FING00000060 | 0.19 |
| 4561 | PSIP1 levels | GCST90470354 | 0.19 |
| 4562 | systolic blood pressure (SBP, mean, inv-normal transformed) | GCST90476403 | 0.19 |
| 4563 | Autorefraction - 6mm strong meridian (right) | Eyesight | UKBB00000076 | 0.19 |
| 4564 | Docosahexaenoic acid to total fatty acids percentage | GCST90501999 | 0.19 |
| 4565 | IDP dMRI TBSS L3 Posterior limb of internal capsule L | GCST90004190 | 0.19 |
| 4566 | HippSubfield rh volume CA1-head | GCST90002696 | 0.19 |
| 4567 | ARF6 levels | GCST90468348 | 0.19 |
| 4568 | Cholesterol to total lipids in IDL percentage (UKB data field 23610) | GCST90269707 | 0.19 |
| 4569 | Chronic ulcer of skin (PheCode 707) | GCST90476216 | 0.19 |
| 4570 | LTA4H levels | GCST90469812 | 0.19 |
| 4571 | NECTIN2/NPDC1 ratio | GCST90315528 | 0.19 |
| 4572 | 1-(1-enyl-stearoyl)-GPE (p-18:0) levels | GCST90199910 | 0.19 |
| 4573 | Pyruvate levels | GCST90092942 | 0.19 |
| 4574 | Free cholesterol to total lipids in medium VLDL percentage (UKB data field 23597) | GCST90269694 | 0.19 |
| 4575 | TDRKH/TST ratio | GCST90315913 | 0.19 |
| 4576 | Pain in throat and chest | Symptoms and signs involving the circulatory and respiratory systems | UKBB00000625 | 0.19 |
| 4577 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T454 | ECGU000454 | 0.19 |
| 4578 | APBB1IP levels | GCST90468327 | 0.19 |
| 4579 | Concentration of small VLDL particles | GCST90092975 | 0.19 |
| 4580 | T1 CAT volume L VIIIa | GCST90384127 | 0.19 |
| 4581 | Systolic blood pressure (BMI unadjusted) | GCST90335162 | 0.19 |
| 4582 | Isoleucine levels (UKB data field 23465) | GCST90269562 | 0.19 |
| 4583 | Cholesterol to total lipids ratio in small HDL | GCST90092945 | 0.19 |
| 4584 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T95 | ECGA000095 | 0.19 |
| 4585 | Autorefraction - 3mm strong meridian (right) | Eyesight | UKBB00000066 | 0.19 |
| 4586 | Peripheral or central vertigo (PheCode 386.2) | GCST90475907 | 0.19 |
| 4587 | Diastolic blood pressure | GCST90301699 | 0.18 |
| 4588 | FADD/GRAP2 ratio | GCST90314766 | 0.18 |
| 4589 | UPB1 levels | GCST90471013 | 0.18 |
| 4590 | ART3/RGMB ratio | GCST90313363 | 0.18 |
| 4591 | Triacylglycerol_52:1_[M+NH4]1+ levels | GCST90060515 | 0.18 |
| 4592 | Mosaic chromosomal alteration of the X chromosome | GCST90165287 | 0.18 |
| 4593 | IDP T1 FAST ROIs R postcent gyrus | GCST90002484 | 0.18 |
| 4594 | aseg lh intensity Cerebellum-Cortex | GCST90003767 | 0.18 |
| 4595 | total cholesterol (minimum, inv-norm transformed) | GCST90476427 | 0.18 |
| 4596 | Dermatitis due to ingested food | FING00000403 | 0.18 |
| 4597 | IL18BP/ROR1 ratio | GCST90315155 | 0.18 |
| 4598 | HDL cholesterol levels (UKB data field 23406) | GCST90269503 | 0.18 |
| 4599 | Takes medication for high blood pressure? | GCST90475216 | 0.18 |
| 4600 | REG4 levels | GCST90470451 | 0.18 |
| 4601 | Triglyceride levels in very large VLDL | GCST90093026 | 0.18 |
| 4602 | aparc-a2009s lh area G-precentral | GCST90003325 | 0.18 |
| 4603 | CLMP/TNFRSF19 ratio | GCST90314136 | 0.18 |
| 4604 | Omega-3 fatty acids to Omega-6 fatty acids ratio | GCST90502074 | 0.18 |
| 4605 | PRL levels | GCST90470332 | 0.18 |
| 4606 | TRIM40 levels | GCST90470968 | 0.18 |
| 4607 | CXCL1 levels | GCST90012019 | 0.18 |
| 4608 | Cholesteryl ester_18:0_[M+NH4]1+ levels | GCST90060222 | 0.18 |
| 4609 | NUDT5/RWDD1 ratio | GCST90315580 | 0.18 |
| 4610 | TNFRSF11B/TNFSF11 ratio | GCST90315930 | 0.18 |
| 4611 | aparc-a2009s rh volume S-orbital-H-Shaped | GCST90003062 | 0.18 |
| 4612 | FURIN levels | GCST90469277 | 0.18 |
| 4613 | Citrate levels | GCST90243442 | 0.18 |
| 4614 | Migraine with aura and triptan purchases | FING00000820 | 0.18 |
| 4615 | DKK3/LTBP2 ratio | GCST90314487 | 0.18 |
| 4616 | aparc-a2009s lh volume G-front-inf-Triangul | GCST90002938 | 0.18 |
| 4617 | Mean corpuscular volume | GCST90018746 | 0.18 |
| 4618 | Guanidinoacetate levels | GCST90200384 | 0.18 |
| 4619 | IDP dMRI TBSS MD Cingulum hippocampus R | GCST90004063 | 0.18 |
| 4620 | THBD levels | GCST90012048 | 0.18 |
| 4621 | Left ventricular end diastolic mass end diastolic volume ratio | GCST90268131 | 0.18 |
| 4622 | Cholesteryl esters to total lipids in chylomicrons and extremely large VLDL percentage (UKB data field 23581) | GCST90269678 | 0.18 |
| 4623 | AXIN1/CDKN1A ratio | GCST90313403 | 0.18 |
| 4624 | LAT/MANF ratio | GCST90315284 | 0.18 |
| 4625 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T188 | ECGU000188 | 0.18 |
| 4626 | CDC37/PPP1R12A ratio | GCST90313934 | 0.18 |
| 4627 | Hemorrhoids | circulatory system | UKBB00000325 | 0.18 |
| 4628 | Free cholesterol in very small VLDL | GCST90500777 | 0.18 |
| 4629 | Fibroblastic disorders | FING00000542 | 0.18 |
| 4630 | Phospholipids to Total Lipids in Very Small VLDL percentage | GCST90500856 | 0.18 |
| 4631 | Degree of unsaturation | GCST90502224 | 0.18 |
| 4632 | CDH1/CST3 ratio | GCST90313946 | 0.18 |
| 4633 | Hair colour (natural, before greying): Dark brown (UKB data field 1747_4) | GCST90041839 | 0.18 |
| 4634 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T117 | ECGU000117 | 0.18 |
| 4635 | Pain type(s) experienced in last month - Pain all over the body | Pain | UKBB00000632 | 0.18 |
| 4636 | COMP/ITGAV ratio | GCST90314190 | 0.18 |
| 4637 | DPP6/NELL2 ratio | GCST90314541 | 0.18 |
| 4638 | Postinfectious hypothyroidism | FING00001192 | 0.18 |
| 4639 | Osteomyelitis, periostitis, and other infections involving bone (PheCode 710) | GCST90476220 | 0.18 |
| 4640 | Triglyceride levels in small LDL | GCST90092966 | 0.18 |
| 4641 | Operation code - tonsillectomy +/- adenoids | Operations | UKBB00000567 | 0.18 |
| 4642 | Microscopic colitis | GCST90204144 | 0.18 |
| 4643 | Acetone levels (UKB data field 23477) | GCST90269574 | 0.18 |
| 4644 | Abdominal subcutaneous adipose tissue normalized | GCST90267348 | 0.18 |
| 4645 | Mouth/teeth dental problems - Bleeding gums | Mouth | UKBB00000485 | 0.18 |
| 4646 | Low density lipoprotein cholesterol levels | GCST90002412 | 0.18 |
| 4647 | Biological Father: Cancer, Skin | GCST90475240 | 0.18 |
| 4648 | Sacroiliitis, not elsewhere classified | FING00001273 | 0.18 |
| 4649 | CCL8 levels | GCST90468586 | 0.18 |
| 4650 | Age high blood pressure diagnosed | Medical conditions | UKBB00000016 | 0.18 |
| 4651 | DNMBP/WWP2 ratio | GCST90314522 | 0.17 |
| 4652 | ATOX1/SNAP29 ratio | GCST90313374 | 0.17 |
| 4653 | Free cholesterol in medium HDL | GCST90498563 | 0.17 |
| 4654 | Phospholipids to Total Lipids in Small LDL percentage | GCST90499700 | 0.17 |
| 4655 | Cholesterol in very large HDL (UKB data field 23554) | GCST90269651 | 0.17 |
| 4656 | Basophil percentage of white cells variance | GCST90565688 | 0.17 |
| 4657 | Exotropia | GCST90572737 | 0.17 |
| 4658 | Right ventricular ejection fraction | GCST90268117 | 0.17 |
| 4659 | EIF4G1/PLA2G4A ratio | GCST90314638 | 0.17 |
| 4660 | Polyunsaturated fatty acids to monounsaturated fatty acids ratio (UKB data field 23458) | GCST90269555 | 0.17 |
| 4661 | Triglycerides to total lipids in very small VLDL percentage (UKB data field 23608) | GCST90269705 | 0.17 |
| 4662 | Cancer of kidney and renal pelvis (PheCode 189.1) | GCST90475595 | 0.17 |
| 4663 | Left-hemisphere visual network to right-hemisphere default mode network white-matter structural connectivity | GCST90302661 | 0.17 |
| 4664 | Cholesterol levels in small LDL | GCST90092956 | 0.17 |
| 4665 | Ratio of bis-allylic bonds to double bonds in lipids | GCST90132744 | 0.17 |
| 4666 | RRM2B levels | GCST90470500 | 0.17 |
| 4667 | KITLG/PLTP ratio | GCST90315252 | 0.17 |
| 4668 | HSPB6/SNCG ratio | GCST90315090 | 0.17 |
| 4669 | MAN1A2 levels | GCST90469843 | 0.17 |
| 4670 | Saturated fatty acids to total fatty acids percentage | GCST90502685 | 0.17 |
| 4671 | Diabetes mellitus (PheCode 250) | GCST90475658 | 0.17 |
| 4672 | ITPR1 levels | GCST90469655 | 0.17 |
| 4673 | Alkylphosphatidylcholine (O-32:1) levels | GCST90024923 | 0.17 |
| 4674 | aparc-DKTatlas lh volume parstriangularis | GCST90002880 | 0.17 |
| 4675 | IDP dMRI TBSS L1 Inferior cerebellar peduncle L | GCST90004086 | 0.17 |
| 4676 | 4-androsten-3beta,17beta-diol disulfate 2 levels | GCST90243880 | 0.17 |
| 4677 | Left ventricular end diastole inferior wall thickness | GCST90278515 | 0.17 |
| 4678 | Triglycerides in very small VLDL | GCST90500873 | 0.17 |
| 4679 | Placental weight (fetal genotype, adjusted for sex) | GCST90275197 | 0.17 |
| 4680 | PGA4 levels | GCST90470216 | 0.17 |
| 4681 | Impedance of arm (left) | Impedance measures | UKBB00000356 | 0.17 |
| 4682 | Type 2 diabetes (PheCode 250.2) | GCST90475667 | 0.17 |
| 4683 | KDM3A levels | GCST90469671 | 0.17 |
| 4684 | SNAP23/SNAP29 ratio | GCST90315855 | 0.17 |
| 4685 | CPB1 levels | GCST90240597 | 0.17 |
| 4686 | CELA3A levels | GCST90468702 | 0.17 |
| 4687 | Cancer code, self-reported - basal cell carcinoma | Medical conditions | UKBB00000117 | 0.17 |
| 4688 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T496 | ECGU000496 | 0.17 |
| 4689 | Hypertension | GCST90468135 | 0.17 |
| 4690 | IDP dMRI ProbtrackX L1 atr r | GCST90004249 | 0.17 |
| 4691 | TGFB1 levels | GCST90274818 | 0.17 |
| 4692 | HippSubfield rh volume molecular-layer-HP-head | GCST90002699 | 0.17 |
| 4693 | CSNK1D levels | GCST90468888 | 0.17 |
| 4694 | Systolic blood pressure (MTAG) | GCST90449056 | 0.16 |
| 4695 | Phospholipid levels in small VLDL | GCST90092976 | 0.16 |
| 4696 | INSL4 levels | GCST90469621 | 0.16 |
| 4697 | Omega-3 fatty acids to total fatty acids percentage | GCST90502087 | 0.16 |
| 4698 | 1-methylhistidine metabolite level | GCST90615480 | 0.16 |
| 4699 | BA-exvivo rh volume V2 | GCST90002859 | 0.16 |
| 4700 | MFGE8 levels | GCST90469900 | 0.16 |
| 4701 | PLXNA4/USP8 ratio | GCST90315690 | 0.16 |
| 4702 | aparc-a2009s rh area S-intrapariet+P-trans | GCST90003426 | 0.16 |
| 4703 | Impedance of arm right (UKB data field 23109) | GCST90468172 | 0.16 |
| 4704 | CAMSAP1 levels | GCST90468535 | 0.16 |
| 4705 | T1 CAT volume L TemporalOccipitalFusiformCortex | GCST90384076 | 0.16 |
| 4706 | aseg rh intensity Lateral-Ventricle | GCST90003778 | 0.16 |
| 4707 | Phenylalanine levels | GCST90499223 | 0.16 |
| 4708 | Calculus of kidney (PheCode 594.1) | GCST90476145 | 0.16 |
| 4709 | SLC27A4/TDRKH ratio | GCST90315851 | 0.16 |
| 4710 | COL4A1 levels | GCST90468818 | 0.16 |
| 4711 | IDP T1 FAST ROIs L cerebellum I-IV | GCST90002562 | 0.16 |
| 4712 | Peak expiratory flow | GCST007430 | 0.16 |
| 4713 | HSPG2/IGFBP6 ratio | GCST90315091 | 0.16 |
| 4714 | mean corpuscular hemoglobin concentration (MCHC, minimum, inv-norm transformed) | GCST90475460 | 0.16 |
| 4715 | C7 levels | GCST90422332 | 0.16 |
| 4716 | CASP3/SNAP23 ratio | GCST90313644 | 0.16 |
| 4717 | SNX9/VASH1 ratio | GCST90315866 | 0.16 |
| 4718 | Takes medication for Diabetes/sugar? | GCST90475268 | 0.16 |
| 4719 | DKK1/PPCDC ratio | GCST90314477 | 0.16 |
| 4720 | total cholesterol (maximum, inv-norm transformed) | GCST90476420 | 0.16 |
| 4721 | Asthma-related pneumonia | FING00000119 | 0.16 |
| 4722 | BIRC2 levels | GCST90468446 | 0.16 |
| 4723 | Triglycerides to total lipids ratio in small LDL | GCST90092967 | 0.16 |
| 4724 | Impedance of arm left (UKB data field 23110) | GCST90468171 | 0.16 |
| 4725 | Red cell distribution width | GCST004621 | 0.16 |
| 4726 | Rheumatoid arthritis and other inflammatory polyarthropathies | musculoskeletal | UKBB00000758 | 0.16 |
| 4727 | Glucose | Blood biochemistry | UKBB00000288 | 0.16 |
| 4728 | Malignant neoplasm of kidney, except pelvis (PheCode 189.11) | GCST90475597 | 0.16 |
| 4729 | KITLG levels | GCST90428432 | 0.16 |
| 4730 | BA-exvivo rh area V2 | GCST90003231 | 0.16 |
| 4731 | FCER2/FCRL1 ratio | GCST90314789 | 0.16 |
| 4732 | DTI autoptx FA unc r tract | GCST90385138 | 0.16 |
| 4733 | MME levels | GCST90469914 | 0.16 |
| 4734 | IDP dMRI TBSS L2 Fornix | GCST90004128 | 0.16 |
| 4735 | aparc-a2009s rh volume Pole-occipital | GCST90003040 | 0.16 |
| 4736 | Phospholipids in medium VLDL | GCST90499024 | 0.16 |
| 4737 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T444 | ECGU000444 | 0.16 |
| 4738 | Triglyceride levels in medium VLDL | GCST90092926 | 0.16 |
| 4739 | High light scatter reticulocyte count (UKB data field 30300) | GCST90468076 | 0.16 |
| 4740 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T101 | ECGU000101 | 0.16 |
| 4741 | CD40LG/EDAR ratio | GCST90313818 | 0.16 |
| 4742 | Testosterone levels | GCST90483487 | 0.16 |
| 4743 | Stearate 18:0 levels | GCST90243431 | 0.16 |
| 4744 | Plasma mannonate* levels in chronic kidney disease | GCST90265479 | 0.16 |
| 4745 | CSNK2A1 or CSNK2B levels | GCST90088963 | 0.16 |
| 4746 | Disorders of lipid metabolism (PheCode 272) | GCST90475715 | 0.16 |
| 4747 | Infective dermatitis | FING00000673 | 0.16 |
| 4748 | GP2 levels | GCST90469382 | 0.16 |
| 4749 | Asthma | GCST90476024 | 0.16 |
| 4750 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T94 | ECGA000094 | 0.16 |
| 4751 | Cholesteryl Esters to Total Lipids in Large HDL percentage | GCST90497763 | 0.16 |
| 4752 | MSRA/P4HB ratio | GCST90315495 | 0.15 |
| 4753 | Medication use (adrenergics, inhalants) | GCST90018779 | 0.15 |
| 4754 | CD40 levels | GCST90012065 | 0.15 |
| 4755 | IDP dMRI ProbtrackX L3 ptr r | GCST90004320 | 0.15 |
| 4756 | CFH levels | GCST90468729 | 0.15 |
| 4757 | CX3CL1 levels | GCST90274778 | 0.15 |
| 4758 | HSD11B1 levels | GCST90469482 | 0.15 |
| 4759 | TRIM5 levels | GCST90470970 | 0.15 |
| 4760 | Ceramide_40:1_[M-H]1- levels | GCST90060198 | 0.15 |
| 4761 | NPDC1 levels | GCST90470069 | 0.15 |
| 4762 | Cholesteryl esters to total lipids in medium HDL percentage (UKB data field 23641) | GCST90269738 | 0.15 |
| 4763 | TGFBI levels | GCST90470845 | 0.15 |
| 4764 | CPM/LAMP2 ratio | GCST90314215 | 0.15 |
| 4765 | IDP dMRI TBSS L1 Cerebral peduncle L | GCST90004090 | 0.15 |
| 4766 | REG1A/REG4 ratio | GCST90315762 | 0.15 |
| 4767 | Main speciality of consultant (recoded) - Ophthalmology | Summary Administration | UKBB00000419 | 0.15 |
| 4768 | HBEGF/SDC4 ratio | GCST90315037 | 0.15 |
| 4769 | Other and unspecified anaemias | FING00000925 | 0.15 |
| 4770 | Cholesteryl ester_18:1_[M+NH4]1+ levels | GCST90060221 | 0.15 |
| 4771 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T446 | ECGU000446 | 0.15 |
| 4772 | Descending aorta distensibility | GCST90267386 | 0.15 |
| 4773 | Cholesterol to total lipids ratio in chylomicrons and extremely large VLDL | GCST90093041 | 0.15 |
| 4774 | Cholesterol to total lipids ratio in small LDL | GCST90092957 | 0.15 |
| 4775 | Parental longevity (combined parental age at death) | GCST006702 | 0.15 |
| 4776 | TNFRSF11B levels | GCST90012002 | 0.15 |
| 4777 | Other/unspecified rheumatoid arthritis | FING00001126 | 0.15 |
| 4778 | IDP dMRI TBSS OD Body of corpus callosum | GCST90004405 | 0.15 |
| 4779 | IDP dMRI TBSS L1 Posterior limb of internal capsule L | GCST90004094 | 0.15 |
| 4780 | Cholesteryl esters to total lipids ratio in large LDL | GCST90092859 | 0.15 |
| 4781 | CD59 levels | GCST90468639 | 0.15 |
| 4782 | Total lipids in large LDL | GCST90498011 | 0.15 |
| 4783 | Average diameter for VLDL particles | GCST90500279 | 0.15 |
| 4784 | IDP dMRI TBSS MD Posterior thalamic radiation L | GCST90004056 | 0.15 |
| 4785 | PAMR1/RARRES2 ratio | GCST90315595 | 0.15 |
| 4786 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T100 | ECGA000100 | 0.15 |
| 4787 | Metabolic disorders | FING00000816 | 0.15 |
| 4788 | NCAM2 levels | GCST90470004 | 0.15 |
| 4789 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T449 | ECGU000449 | 0.15 |
| 4790 | Cervicobrachial syndrome | FING00000266 | 0.15 |
| 4791 | mean corpuscular hemoglobin concentration (MCHC, maximum, inv-norm transformed) | GCST90475454 | 0.15 |
| 4792 | Free cholesterol in medium VLDL (UKB data field 23507) | GCST90269604 | 0.15 |
| 4793 | N-acetylalanine levels | GCST90200303 | 0.15 |
| 4794 | Autorefraction - 6mm weak meridian (left) | Eyesight | UKBB00000079 | 0.15 |
| 4795 | Number of diet questionnaires completed | Diet questionnaire performance | UKBB00000536 | 0.15 |
| 4796 | Reticulocyte fraction of red cells | GCST004619 | 0.15 |
| 4797 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T459 | ECGU000459 | 0.15 |
| 4798 | Glycine levels | GCST90497316 | 0.15 |
| 4799 | aparc-pial lh area lateraloccipital | GCST90003151 | 0.15 |
| 4800 | Sleep apnoea, including avohilmo | FING00001310 | 0.14 |
| 4801 | DTI TBSS MD External capsule L | GCST90384605 | 0.14 |
| 4802 | IL15RA levels | GCST90469555 | 0.14 |
| 4803 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T68 | ECGA000068 | 0.14 |
| 4804 | Total lipid levels in small VLDL | GCST90092974 | 0.14 |
| 4805 | Nonrheumatic aortic valve disorders (PheCode 395.2) | GCST90475914 | 0.14 |
| 4806 | Autorefraction - 6mm strong meridian (left) | Eyesight | UKBB00000075 | 0.14 |
| 4807 | Phospholipids to total lipids ratio in very large VLDL | GCST90093025 | 0.14 |
| 4808 | Free cholesterol levels in chylomicrons and extremely large VLDL | GCST90500965 | 0.14 |
| 4809 | F5 levels | GCST90446466 | 0.14 |
| 4810 | Colorectal cancer | GCST90018588 | 0.14 |
| 4811 | C1QTNF1/COL18A1 ratio | GCST90313551 | 0.14 |
| 4812 | Omega-3 fatty acids to total fatty acids percentage | GCST90502448 | 0.14 |
| 4813 | Non-cancer illness code, self-reported - gout | Medical conditions | UKBB00000512 | 0.14 |
| 4814 | FXYD5 levels | GCST90469283 | 0.14 |
| 4815 | Normotensive glaucoma | FING00000892 | 0.14 |
| 4816 | FLT4/KDR ratio | GCST90314861 | 0.14 |
| 4817 | Concentration of IDL particles | GCST90497606 | 0.14 |
| 4818 | IDP dMRI TBSS L3 Retrolenticular part of internal capsule R | GCST90004191 | 0.14 |
| 4819 | PRAP1 levels | GCST90470312 | 0.14 |
| 4820 | RNASE3 levels | GCST90470477 | 0.14 |
| 4821 | Cholesteryl Esters in Large VLDL | GCST90498146 | 0.14 |
| 4822 | CELA3A/KIRREL2 ratio | GCST90314013 | 0.14 |
| 4823 | Other disorders of stomach and duodenum (PheCode 537) | GCST90476054 | 0.14 |
| 4824 | Systolic blood pressure | GCST90018752 | 0.14 |
| 4825 | BPIFB2 levels | GCST90468463 | 0.14 |
| 4826 | APOB levels | UKBB00000041 | 0.14 |
| 4827 | VASN levels | GCST90471027 | 0.14 |
| 4828 | High light scatter reticulocyte percentage (UKB data field 30290) | GCST90468077 | 0.14 |
| 4829 | aparc-a2009s rh volume S-calcarine | GCST90003042 | 0.14 |
| 4830 | IDP dMRI TBSS OD Cerebral peduncle R | GCST90004416 | 0.14 |
| 4831 | Cholesterol to total lipids in small HDL percentage (UKB data field 23645) | GCST90269742 | 0.14 |
| 4832 | Phospholipid levels in medium LDL | GCST90092912 | 0.14 |
| 4833 | Attention deficit hyperactivity disorder (ADuLT model adjusted for sex) | GCST90275136 | 0.14 |
| 4834 | BAG6/USP8 ratio | GCST90313451 | 0.14 |
| 4835 | STX8/USP8 ratio | GCST90315896 | 0.14 |
| 4836 | T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 20) | GCST90320839 | 0.14 |
| 4837 | DTI autoptx L3 cgc r tract | GCST90385198 | 0.14 |
| 4838 | DNPH1/PDGFB ratio | GCST90314527 | 0.14 |
| 4839 | NFU1 levels | GCST90470040 | 0.14 |
| 4840 | Infantile hypertrophic pyloric stenosis | GCST006705 | 0.14 |
| 4841 | Cholesterol in small VLDL (UKB data field 23512) | GCST90269609 | 0.14 |
| 4842 | Malignant neoplasm of lip, excluding all cancers (controls excluding all cancers) | FING00000764 | 0.14 |
| 4843 | IDP dMRI TBSS FA Sagittal stratum R | GCST90003907 | 0.14 |
| 4844 | HippSubfield lh volume presubiculum-head | GCST90002673 | 0.14 |
| 4845 | Concentration of large HDL particles | GCST90497828 | 0.14 |
| 4846 | NTRK3 levels | GCST90470098 | 0.14 |
| 4847 | Fracture of radius and ulna (PheCode 803.2) | GCST90476280 | 0.14 |
| 4848 | Other hearing loss | FING00001056 | 0.14 |
| 4849 | Cholesterol levels (UKB data field 30690) | GCST90468066 | 0.14 |
| 4850 | Treatment/medication code - allopurinol | Medications | UKBB00000839 | 0.14 |
| 4851 | Other infective otitis externa | FING00001060 | 0.14 |
| 4852 | Unspecified dementia | FING00001400 | 0.14 |
| 4853 | F13B levels | GCST90469167 | 0.13 |
| 4854 | Calculus of kidney and ureter | Urolithiasis | UKBB00000116 | 0.13 |
| 4855 | Spondyloarthritis | FING00001323 | 0.13 |
| 4856 | T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 72) | GCST90320635 | 0.13 |
| 4857 | HSPG2/PTGDS ratio | GCST90315092 | 0.13 |
| 4858 | Triglyceride levels in small HDL | GCST90092954 | 0.13 |
| 4859 | T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 45) | GCST90320864 | 0.13 |
| 4860 | LPCAT2 levels | GCST90469787 | 0.13 |
| 4861 | Ventral hernia (PheCode 550.5) | GCST90476063 | 0.13 |
| 4862 | Phospholipids to Total Lipids in Large LDL percentage | GCST90498071 | 0.13 |
| 4863 | IDP dMRI ProbtrackX FA ilf r | GCST90003940 | 0.13 |
| 4864 | GCHFR levels | GCST90469317 | 0.13 |
| 4865 | Other dorsopathies, not elsewhere classified | FING00001041 | 0.13 |
| 4866 | Triglyceride levels in VLDL | GCST90093003 | 0.13 |
| 4867 | Systolic blood pressure (BMI adjusted) | GCST90335163 | 0.13 |
| 4868 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T437 | ECGU000437 | 0.13 |
| 4869 | RHOC/TBCC ratio | GCST90315775 | 0.13 |
| 4870 | eGFR in diabetes mellitus (loose) case-control group (minimal adjustment) | GCST90624790 | 0.13 |
| 4871 | RPE levels | GCST90470495 | 0.13 |
| 4872 | ADAMTSL4 levels | GCST90468229 | 0.13 |
| 4873 | Cholesteryl Esters in Medium LDL | GCST90498738 | 0.13 |
| 4874 | Concentration of VLDL particles | GCST90093000 | 0.13 |
| 4875 | Hypertension (confirmatory factor analysis Factor 12) | GCST90309346 | 0.13 |
| 4876 | Asthma | GCST90475259 | 0.13 |
| 4877 | X-12216 levels | GCST90200483 | 0.13 |
| 4878 | Ulcerative colitis, NAS | FING00001390 | 0.13 |
| 4879 | APOA levels | UKBB00000040 | 0.13 |
| 4880 | ITGBL1 levels | GCST90469648 | 0.13 |
| 4881 | Cancer of prostate | neoplasms | UKBB00000118 | 0.13 |
| 4882 | High blood pressure / hypertension | GCST90475214 | 0.13 |
| 4883 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T67 | ECGU000067 | 0.13 |
| 4884 | Glucose (fasting status unknown, maximum, inv-norm transformed) | GCST90475329 | 0.13 |
| 4885 | Free cholesterol to total lipids in large LDL percentage (UKB data field 23617) | GCST90269714 | 0.13 |
| 4886 | Fracture of lower limb | injuries & poisonings | UKBB00000255 | 0.13 |
| 4887 | ThalamNuclei rh volume Pf | GCST90002746 | 0.13 |
| 4888 | LAYN/TNFRSF4 ratio | GCST90315291 | 0.13 |
| 4889 | aparc-a2009s rh area G-precuneus | GCST90003400 | 0.13 |
| 4890 | Right molecular layer hippocampal volume (body) | GCST90267975 | 0.13 |
| 4891 | Vertiginous syndromes and other disorders of vestibular system (PheCode 386) | GCST90475905 | 0.13 |
| 4892 | Triglyceride to HDL cholesterol ratio | GCST90295949 | 0.13 |
| 4893 | PRSS22 levels | GCST90470341 | 0.13 |
| 4894 | Free cholesterol in medium HDL | GCST90498562 | 0.13 |
| 4895 | Triglyceride levels in small VLDL | GCST90092978 | 0.13 |
| 4896 | Triglycerides to total lipids in medium LDL percentage (UKB data field 23623) | GCST90269720 | 0.13 |
| 4897 | DNM3 levels | GCST90469022 | 0.13 |
| 4898 | Platelet count during postpartum period | GCST90302228 | 0.13 |
| 4899 | aparc-Desikan lh volume parsopercularis | GCST90002785 | 0.13 |
| 4900 | Free cholesterol levels in very small VLDL | GCST90093032 | 0.13 |
| 4901 | PDGFB/SPARC ratio | GCST90315628 | 0.13 |
| 4902 | Linoleic acid levels | GCST90498306 | 0.13 |
| 4903 | Omega-3 fatty acids to Omega-6 fatty acids ratio | GCST90502396 | 0.13 |
| 4904 | Phosphatidylcholine_33:4_[M+H]1+/Phosphatidylethanolamine_36:4_[M+H]1+/Phosphatidate_38:5_[M+NH4]1+ levels | GCST90060273 | 0.13 |
| 4905 | FADD levels | GCST90469180 | 0.13 |
| 4906 | 3-methyl-2-oxovalerate levels | GCST90243485 | 0.13 |
| 4907 | Triglycerides in chylomicrons and extremely large VLDL (UKB data field 23487) | GCST90269584 | 0.13 |
| 4908 | Cholesteryl Esters to Total Lipids in Large LDL percentage | GCST90497967 | 0.13 |
| 4909 | Disorders of bilirubin excretion (PheCode 277.4) | GCST90475756 | 0.13 |
| 4910 | T1 FIRST volume R Puta | GCST90383995 | 0.13 |
| 4911 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T2 | ECGA000002 | 0.13 |
| 4912 | Ulcerative colitis (strict) with PSC | FING00001389 | 0.13 |
| 4913 | Total fatty acid levels | GCST90502211 | 0.13 |
| 4914 | CCL20 levels | GCST90468572 | 0.13 |
| 4915 | Cholesterol to total lipids in medium VLDL percentage (UKB data field 23595) | GCST90269692 | 0.13 |
| 4916 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T93 | ECGA000093 | 0.13 |
| 4917 | Central serous chorioretinopathy | GCST90268400 | 0.13 |
| 4918 | Triglyceride to HDL cholesterol ratio | GCST90295951 | 0.13 |
| 4919 | aparc-a2009s rh volume S-oc-middle+Lunatus | GCST90003055 | 0.12 |
| 4920 | CPB1/PRSS2 ratio | GCST90314211 | 0.12 |
| 4921 | VEGFA levels | GCST90471034 | 0.12 |
| 4922 | Dyslipidemia | GCST90086077 | 0.12 |
| 4923 | Hair colour (natural, before greying) - Light brown | Sun exposure | UKBB00000298 | 0.12 |
| 4924 | DTI autoptx L1 ptr r tract | GCST90385159 | 0.12 |
| 4925 | Interpolated Age of participant when non-cancer illness first diagnosed | Medical conditions | UKBB00000369 | 0.12 |
| 4926 | Polyunsaturated fatty acid levels | GCST90502606 | 0.12 |
| 4927 | Urinary calculus (PheCode 594) | GCST90476143 | 0.12 |
| 4928 | Phospholipids to total lipids ratio in very large HDL | GCST90093013 | 0.12 |
| 4929 | Systolic blood pressure | GCST90472780 | 0.12 |
| 4930 | CLEC1B/RWDD1 ratio | GCST90314102 | 0.12 |
| 4931 | Triacylglycerol_53:5_[M+NH4]1+ levels | GCST90060520 | 0.12 |
| 4932 | Cholesteryl esters in VLDL (UKB data field 23416) | GCST90269513 | 0.12 |
| 4933 | Coxarthrosis | FING00000362 | 0.12 |
| 4934 | Two-hour glucose | GCST90002227 | 0.12 |
| 4935 | DKK4/REG1A ratio | GCST90314489 | 0.12 |
| 4936 | MPI levels | GCST90469936 | 0.12 |
| 4937 | wg lh intensity-contrast posteriorcingulate | GCST90003814 | 0.12 |
| 4938 | Triglycerides to total lipids in small LDL percentage (UKB data field 23628) | GCST90269725 | 0.12 |
| 4939 | Bicuspidal aortic valve syndrome | FING00000212 | 0.12 |
| 4940 | Left-hemisphere control network to right-hemisphere visual network white-matter structural connectivity | GCST90302745 | 0.12 |
| 4941 | Other and unspecified psoriasis | FING00000950 | 0.12 |
| 4942 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T63 | ECGA000063 | 0.12 |
| 4943 | Autorefraction - 6mm weak meridian (right) | Eyesight | UKBB00000080 | 0.12 |
| 4944 | CD20 on IgD- CD38- B cell | GCST90001755 | 0.12 |
| 4945 | Lysoalkylphosphatidylcholine (O-24:0) levels | GCST90024812 | 0.12 |
| 4946 | rfMRI amplitudes (ICA100 node 38) | GCST90004626 | 0.12 |
| 4947 | Prescriptions - stimulant laxative|laxative | UKBB00000702 | 0.12 |
| 4948 | Colon polyp | GCST90018607 | 0.12 |
| 4949 | NCAM1 levels | GCST90470003 | 0.12 |
| 4950 | SERPINA5 levels | GCST90470585 | 0.12 |
| 4951 | MOG/SEZ6L ratio | GCST90315477 | 0.12 |
| 4952 | Plasma 16a-hydroxy DHEA 3-sulfate levels in chronic kidney disease | GCST90264328 | 0.12 |
| 4953 | Bronchitis | FING00000228 | 0.12 |
| 4954 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T492 | ECGU000492 | 0.12 |
| 4955 | SEPHS1 levels | GCST90242740 | 0.12 |
| 4956 | NID1/NID2 ratio | GCST90315541 | 0.12 |
| 4957 | Chronic bronchitis (PheCode 496.2) | GCST90476029 | 0.12 |
| 4958 | C2/SSC5D ratio | GCST90313555 | 0.12 |
| 4959 | HAO1 levels | GCST90469429 | 0.12 |
| 4960 | Presence of cardiac and vascular implants and grafts | Persons with potential health hazards related to family and personal history and certain conditions influencing health status | UKBB00000708 | 0.12 |
| 4961 | PNLIP levels | GCST90470275 | 0.12 |
| 4962 | aparc-DKTatlas rh area lingual | GCST90003276 | 0.12 |
| 4963 | Free cholesterol in very large HDL | GCST90500380 | 0.12 |
| 4964 | EBAG9/EDAR ratio | GCST90314563 | 0.12 |
| 4965 | AKT1S1/MAX ratio | GCST90313230 | 0.12 |
| 4966 | Cholesterol to total lipids ratio in large VLDL | GCST90092869 | 0.12 |
| 4967 | PLIN1/SNCG ratio | GCST90315677 | 0.12 |
| 4968 | ThalamNuclei lh volume Whole-thalamus | GCST90002762 | 0.12 |
| 4969 | Diastolic blood pressure | GCST90278625 | 0.12 |
| 4970 | IL18RAP levels | GCST90469566 | 0.12 |
| 4971 | CLMP/PIK3IP1 ratio | GCST90314134 | 0.12 |
| 4972 | wg rh intensity-contrast isthmuscingulate | GCST90003836 | 0.12 |
| 4973 | STX4 levels | GCST90470772 | 0.12 |
| 4974 | Triglycerides in very large HDL | GCST90500481 | 0.12 |
| 4975 | Triglycerides to total lipids ratio in medium LDL | GCST90092915 | 0.12 |
| 4976 | Gallstone disease | GCST90128518 | 0.12 |
| 4977 | Cholesterol to total lipids ratio in small VLDL | GCST90092969 | 0.12 |
| 4978 | LAG3/VCAM1 ratio | GCST90315270 | 0.12 |
| 4979 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T129 | ECGU000129 | 0.12 |
| 4980 | T1 FreeSurfer DK rh pericalcarine area | GCST90385709 | 0.12 |
| 4981 | Mean arterial pressure (BMI unadjusted) | GCST90335168 | 0.12 |
| 4982 | Triglycerides to total lipids in medium VLDL percentage (UKB data field 23598) | GCST90269695 | 0.12 |
| 4983 | CD99L2/CPM ratio | GCST90313925 | 0.11 |
| 4984 | BTN2A1/LILRB4 ratio | GCST90313546 | 0.11 |
| 4985 | Free cholesterol in very small VLDL (UKB data field 23521) | GCST90269618 | 0.11 |
| 4986 | PLIN3 levels | GCST90470259 | 0.11 |
| 4987 | Isoleucine levels | GCST90092843 | 0.11 |
| 4988 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T456 | ECGU000456 | 0.11 |
| 4989 | BA-exvivo rh volume BA3a | GCST90002851 | 0.11 |
| 4990 | Number of operations, self-reported | Operations | UKBB00000539 | 0.11 |
| 4991 | IDP dMRI TBSS L3 Retrolenticular part of internal capsule L | GCST90004192 | 0.11 |
| 4992 | CD20 on IgD- CD24- B cell | GCST90001753 | 0.11 |
| 4993 | PTH1R levels | GCST90470371 | 0.11 |
| 4994 | Deep vein thrombosis [DVT] (PheCode 452.2) | GCST90476010 | 0.11 |
| 4995 | ThalamNuclei lh volume MDl | GCST90002724 | 0.11 |
| 4996 | CA13 levels | GCST90468508 | 0.11 |
| 4997 | Muscular dystrophy | FING00000848 | 0.11 |
| 4998 | SLC35G2 levels | GCST90242857 | 0.11 |
| 4999 | PDGFC/TFPI ratio | GCST90315636 | 0.11 |
| 5000 | ThalamNuclei rh volume MGN | GCST90002737 | 0.11 |